Oncolytics Biotech Inc. (NASDAQ:ONCY)
Oncolytics Biotech Inc. is focused on the development of oncolytic viruses as a novel and effective approach to cancer treatment. Oncolytics’ lead product, REOLYSIN, is developed from the human reovirus.
Market Data
Download
Recent News
- Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch 2012 Heath Care Conference
- Oncolytics Biotech® Inc. Announces First Quarter 2012 Results
- Oncolytics Biotech® Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Colorectal Cancer
- Oncolytics Biotech® Inc. to Present at 11th Annual Needham Healthcare Conference
- Trials Show Promise of Human Virus to Treat Head and Neck Cancer Patients
- Oncolytics Biotech® Inc. Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers
- Oncolytics Biotech® Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
- Oncolytics Biotech® Inc. Announces 2011 Year End Results
- Oncolytics Biotech® Inc. to Present at Cowen and Company 32nd Annual Health Care Conference
- Oncolytics Biotech® Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer
- OncoSec President and CEO Contributes to Physicians News Digest
- Multidisciplinary Care for Colorectal Cancer
- Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial of REOLYSIN® in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint
- Oncolytics Biotech® Inc. Announces Start of Conformity Testing with SAFC®
- Oncolytics Biotech® Inc. Collaborators to Present Positive Phase 2 REOLYSIN Clinical Data in Pancreatic Cancer at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Contacts & RSS
Investor Relations
Erika Moran
Public Relations
Janet Vasquez
Phone
212.825.3210
